Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer
- 7 May 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 26 (49), 6997-7005
- https://doi.org/10.1038/sj.onc.1210506
Abstract
The 11q13 region is amplified in approximately 15% of all breast tumors. Situated in this region are the cyclin D1 gene (CCND1) and the p-21-activated kinase 1 (PAK1) gene. Both genes encode proteins shown to activate the estrogen receptor (ER), leading to transcription of CCND1 and other ER-responsive genes. Here, we investigate the prognostic and treatment predictive role of CCND1 and PAK1 gene amplification in postmenopausal breast cancer patients randomized to tamoxifen treatment or no adjuvant treatment. Amplification of CCND1 and PAK1, assessed by real-time PCR, was observed in 12.5 and 9.3%, respectively. Amplification of PAK1 was seen in 37% of the CCND1-amplified tumors, indicating coamplification (PP=0.025). When response to tamoxifen treatment was analysed, patients with PAK1 amplification showed decreased benefit from the drug (ER+; relative risk ratio (RR)=1.62; 95% confidence interval (CI), 0.47–5.55) compared to patients without amplification (ER+; RR=0.53; 95% CI, 0.32–0.88). This was not evident for CCND1 amplification. We show that PAK1 may be a predictor of tamoxifen resistance and furthermore, we do not discard PAK1 as a potential candidate oncogene in the 11q13 amplicon. In addition, we show that high pak1 protein levels may predict tamoxifen insensitivity.Keywords
This publication has 39 references indexed in Scilit:
- Gene amplification in cancerTrends in Genetics, 2006
- Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomasGynecologic Oncology, 2006
- Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistanceBreast Cancer Research and Treatment, 2005
- Prognostic Relevance of Gene Amplifications and Coamplifications in Breast CancerCancer Research, 2004
- Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cellsFEBS Letters, 2004
- Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patientsActa Oncologica, 2004
- p21-activated Kinase-1 Signaling Mediates Cyclin D1 Expression in Mammary Epithelial and Cancer CellsPublished by Elsevier BV ,2004
- Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assaysBritish Journal of Cancer, 2002
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinomaCytogenetic and Genome Research, 1997